Cargando…

Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma

Antiangiogenic therapy is theoretically a promising anticancer approach but does not always produce significant tumor control. Combinations of antiangiogenic therapies are therefore being investigated as strategies to enhance clinical benefit. Common targets for angiogenic blockade include endotheli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adamcic, Una, Castagna, Clorinda, Minhas, Kanwal, Shahrzad, Siranoush, Coomber, Brenda L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189601/ https://www.ncbi.nlm.nih.gov/pubmed/22007215 http://dx.doi.org/10.1155/2012/794172

Ejemplares similares

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

Differential Expression of Tie2 Receptor and VEGFR2 by Endothelial Clones Derived from Isolated Bovine Mononuclear Cells
por: Adamcic, Una, et al.
Publicado: (2012)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Antitumor and Antiangiogenic Activities of Curcumin in Cervical Cancer Xenografts in Nude Mice
por: Yoysungnoen-Chintana, Pornphrom, et al.
Publicado: (2014)

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma
por: Chen, Zhuo, et al.
Publicado: (2015)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2017)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?
por: Cidon, E. Una, et al.
Publicado: (2016)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
por: Dolan, Melissa, et al.
Publicado: (2019)

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
por: Helfrich, Iris, et al.
Publicado: (2010)

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma
por: Helfrich, Iris, et al.
Publicado: (2013)

Monitoring Treatment Efficacy of Antiangiogenic Therapy Combined With Hypoxia-Activated Prodrugs Online Using Functional MRI
por: Ma, Mengjie, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2010)

Antiangiogenic therapies in ovarian cancer
por: Reinthaller, Alexander
Publicado: (2016)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Antiangiogenic Therapy for Diabetic Nephropathy
por: Tanabe, Katsuyuki, et al.
Publicado: (2017)

Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model
por: ZHANG, XIAO-HUA, et al.
Publicado: (2013)

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography
por: Zhu, Xiao-Dong, et al.
Publicado: (2011)

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
por: Ebos, John ML, et al.
Publicado: (2014)

Dynamic radiomics for predicting the efficacy of antiangiogenic therapy in colorectal liver metastases
por: Qu, Hui, et al.
Publicado: (2023)

Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy
por: Yonucu, Sirin, et al.
Publicado: (2017)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
por: Mougel, Alice, et al.
Publicado: (2019)

Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy
por: Rajora, Amit Kumar, et al.
Publicado: (2020)

Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy
por: Jin, Chengwen, et al.
Publicado: (2022)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Antiangiogenic Steroids in Human Cancer Therapy
por: Pietras, Richard J., et al.
Publicado: (2005)

New perspectives in glioblastoma antiangiogenic therapy
por: Popescu, Alisa Madalina, et al.
Publicado: (2015)

Efficacy and safety of PD‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study
por: Yao, Junlin, et al.
Publicado: (2022)

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
por: Verheul, H M W, et al.
Publicado: (1999)

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?
por: Wenger, Justin B., et al.
Publicado: (2011)

Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI
por: Rajendran, Reshmi, et al.
Publicado: (2014)

Additive Antiproliferative and Antiangiogenic Effects of Metformin and Pemetrexed in a Non-Small-Cell Lung Cancer Xenograft Model
por: Wang, Jiun-Long, et al.
Publicado: (2021)

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Inhibitory effects of icotinib combined with antiangiogenic drugs in human non‐small cell lung cancer xenograft models are better than single target drugs
por: Jiang, Peng, et al.
Publicado: (2021)

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety
por: Welker, Martin-Walter, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_99f0m2c00u7cl5a3lgln48r11u